RESULTS: We confirm that like decreased FOXA1 expression, decreased PTEN is common in bladder cancer. However, decreased PTEN expression is not associated with a specific morphologic characteristic or gene expression subtype. We show copy number alterations are likely a major factor determining PTEN expression, while FOXA1 expression is relatively independent of copy number. Combined inactivation of Foxa1 and Pten in mice results in the development of bladder cancer with squamous features. Additionally, exposure of these mice to a bladder-specific carcinogen results in rapid development of advanced disease with extensive squamous differentiation.
INTRODUCTION AND OBJECTIVES:
There is presently a major discrepancy between the critical role of PTEN knockout in the genesis of muscle-invasive bladder cancer (MIBC) in mice and the very low frequency (6-8%) of PTEN mutation or deletion in the human counterpart. We undertook this study to examine the alternative mechanism(s) of PTEN inactivation, and found hyper-phosphorylation of PTEN, which functionally disables PTEN, to be extremely prevalent in human MIBC. This has several major theranostic implications.
METHODS: The status of PTEN and its phosphorylation were first assessed in a panel of human bladder cancer (BC) cell lines, and then in a collection of fresh human BC specimens by Western blotting, and then in a cohort of archived low-grade non-invasive and high-grade invasive BC, both with matching adjacent normal urothelial controls, by immunohistochemical (IHC) staining. In the case of PTEN phosphorylation, phosphorylation site-specific antibodies were used. The effects of PTEN phosphorylation in functionally inactivating PTEN were established by transfecting PTEN-lacking BC cell lines (UMUC3 and J82) with wild-type PTEN or PTEN bearing phosphorylationincompatible mutations or deletion. Their effects on cell growth, migration, AKT phosphorylation, cell-cycle progression and apoptosis were assessed in vitro and in xenograft mouse models.
RESULTS: All but two BC cell lines (UMUC3 and J82) expressed PTEN and whenever PTEN was expressed, it was hyperphosphorylated at the C-terminus. By Western blotting of fresh human BC specimens, 10/12 (83%) of the low-grade non-muscle-invasive BC (NMIBC) and high-grade muscle-invasive MIBC contained PTEN, and in all the positive tumors PTEN was hyper-phosphorylated at the C-terminus. By IHC, phosphorylated PTEN was significantly higher in BC, particularly MIBC than matching normal urothelia. Functional studies showed that PTEN phosphorylation drove PTEN from the membrane into the cytoplasm where it was much less active, and that wild-type PTEN was much less effective than PTEN bearing phosphorylation-incompatible amino acids or C-terminal deletion in growth inhibition in vitro and in nude mice.
CONCLUSIONS: PTEN phosphorylation is a major mechanism of inactivation in human bladder cancer, and it should be used as biomarker, instead of PTEN itself, for diagnosing, subtyping and predicting the progression of bladder cancer.
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MP51-14 HYPERCHOLESTEROLEMIA PROMOTES THE PROGRESSION OF BLADDER CANCER IN SEVERAL MICE MODELS.
Lin Yang*, Jun Yan, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Hypercholesterolemia was reported to be associated with several cancers, such as prostate cancer, breast cancer and colorectal cancer. Urinary bladder cancer (UBC) is one of the most common urogenital malignancies. Whether hypercholesterolemia plays a role in UBC progression remains unclear. Our objective was to investigate the influence of hypercholesterolemia on UBC progression by several mice models.
METHODS: 1) Diet induced hypercholesterolemia model. Nude mice were fed with low fat no cholesterol diet (LFNC) or high fat high cholesterol diet (HFHC) w/o ezetimibe (EZ), which inhibited the absorption of cholesterol. T24 xenografts were injected once model established. Tumor growth, etc were measured. 2) BBN induced in situ bladder cancer model in wildtype mice and LDLR-/-mice. Tumor progression was analyzed. 3) MB49 allografts and tail vessel injected lung metastasis model. Allografts' growth and lung metastases were measured.
RESULTS: 1) Diet induced hypercholesterolemia promoted UBC progression (Figure 1) . 2) BBN induced UBC was promoted in LDLR-/-mice, a spontaneous hypercholesterolemia mouse model. UBC in situ progressed much faster in LDLR-/-mice ( Figure 2B ) with more lymph node and lung metastases ( Figure 2C and 2D ). Shorter survival curve was found in LDLR-/-mice ( Figure 2E ). 3) Enhanced progression, metastasis of MB49 injected were found in LDLR-/-mice compared to those in wildtype mice. MB49 allografts' growth was enhanced in LDLR-/-mice with lung metastases which were not detected in wildtype mice ( Figure 3A to 3C ). Tail vessel injection induced lung metastasis of MB49 showed that enhanced metastasis ability was detected in LDLR-/-mice ( Figure 3D to 3F).
CONCLUSIONS: Hypercholesterolemia could promote the progression of UBC, which was confirmed in several mice models.
INTRODUCTION AND OBJECTIVES: Gemcitabine (GEM) and cisplatin (CDDP) combination chemotherapy (GC) is the standard treatment for patients with advanced bladder cancer (BC), but responses have been reported in only 60% of patients, and these are rarely durable. We aimed to use a genomic analysis to determine mechanisms of resistance to GC.
METHODS: Three chemo-sensitive BC cell lines were treated serially with increasing concentrations of CDDP or GEM in order to establish acquired resistance. Gene expression of the resistant cells was compared to the sensitive parental cells. Results were validated in The Cancer Genome Atlas (n[405) and in a patient cohort treated with neoadjuvant GC (n[223). Immunohistochemistry (IHC) was performed in 14 patient tumors before and after neoadjuvant GC and in 37 patients with metastatic BC treated with GC. Correlative in vitro experiments were conducted to explore the mechanism of acquired chemo-resistance.
RESULTS: Gene expression analysis revealed that STAT1 and six interferon-regulated genes were among the most highly upregulated genes in resistant cells. In the TCGA dataset, STAT1 expression correlated with the expression of the other 6 genes (P<0.001). Highest STAT1 expression was observed in basal/ squamous and luminal infiltrated subtypes. Five-year survival in these patients treated without neoadjuvant GC was 49.7% and 47.7% in tumors with high and low STAT1 expression (compared the median), respectively. In a cohort of patients treated with neoadjuvant GC, the corresponding survival was 62.7% and 78.9%. Nuclear STAT1 expression by IHC was absent in tumors prior to GC but detected in 29% after GC, suggesting that GC activates STAT1 in a subset of patients. In patients with metastatic BC, STAT1 expression was higher in patients with progressive disease (P[0.078) and high STAT1 expression correlated with worse prognosis (P[0.012). Knockdown of STAT1 in resistant cells without CDDP/GEM treatment increased cell growth by cell cycle progression, which was accompanied by increased SKP2 and decreased p27. However, STAT1 knockdown with CDDP/GEM treatment decreased cell growth and increased apoptosis, suggesting that STAT1 silencing restored sensitivity to GC.
CONCLUSIONS: STAT1 signaling is activated in a subset of BC patients and is associated with acquired chemotherapy resistance. Pending further validation, STAT1 may be considered as potential target in combination with GC, as well as a predictive marker of response to GC. METHODS: KE1 (ERCC2 mutant, NER defective, cisplatin sensitive) bladder cells and parental KU1919 cells (ERCC2 wild-type, NER proficient, cisplatin resistant) were used. Cell viability was examined using CellTiter-glo. IC50 concentrations were calculated using a four parameter sigmoidal model and plots generated by GraphPad Prism 7. Drug combination indexes (CI) of cisplatin and SP were calculated using Chou-Talalay method. DNA damage response and apoptosis signaling was examined by Western blot of gamma-H2AX, P53, cleaved Caspase-3 and cleaved PARP.
Source of
RESULTS: KU1919 cells are more sensitive to SP (IC50 [ 29.2 vs IC50 [ 37.4 mM). Combinations of cisplatin and SP (5 mM:40 mM) resulted in strong synergy in KU1919 cells (CI [ 0.29), whereas mild synergy of cisplatin and SP (1 mM:40 mM) was observed in KE1 cells (CI [ 0.66) . In a patient derived organoid model, 10 µM SP alone exhibited no cytotoxicity, and combination with 10 mMSP and 25 mMcisplatin significantly decreased cell survival compared with 25 mM cisplatin alone (17.9% vs 32.1%, p<0.01). Following 24 hours 5 mM cisplatin
